Carole Ho is Chief Medical Officer at Denali Therapeutics Inc. (DNLI). They have made 52 open-market trades across 1 company since 2018, most recently 2026-06-05.
CIK 0001724605
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 52 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| DNLI | SELL · 10b5-1 | 2025-08-12 | 2025-08-14 | $13.81 | $52K | +6.7% | -9.7% | +20.2% |
| DNLI | SELL | 2025-01-06 | 2025-01-08 | $20.33 | $617K | +13.9% | +8.7% | -43.9% |
| DNLI | SELL · 10b5-1 | 2024-08-20 | 2024-08-22 | $24.49 | $1.1M | +4.4% | +25.4% | +1.3% |
| DNLI | SELL | 2024-08-13 | 2024-08-15 | $22.89 | $107K | +6.0% | +28.8% | +25.8% |
| DNLI | SELL · 10b5-1 | 2024-02-13 | 2024-02-15 | $17.46 | $73K | +13.7% | +13.0% | +17.3% |
| DNLI | SELL · 10b5-1 | 2024-01-10 | 2024-01-12 | $19.02 | $178K | -5.5% | +1.9% | +5.3% |
| DNLI | SELL | 2024-01-05 | 2024-01-09 | $19.43 | $388K | -11.2% | -11.8% | -2.4% |
| DNLI | SELL | 2023-08-23 | 2023-08-25 | $23.22 | $117K | +5.2% | -4.3% | -19.9% |
| DNLI | SELL | 2023-08-21 | 2023-08-23 | $22.60 | $112K | +4.5% | -2.9% | -20.2% |
| DNLI | SELL · 10b5-1 | 2023-08-14 | 2023-08-16 | $23.79 | $132K | -3.1% | +0.2% | -18.6% |
| DNLI | SELL | 2023-08-10 | 2023-08-14 | $24.15 | $138K | -7.5% | -1.0% | -32.9% |
| DNLI | SELL · 10b5-1 | 2023-02-15 | 2023-02-17 | $29.40 | $43K | -9.5% | -22.2% | +1.2% |
| DNLI | SELL | 2023-02-10 | 2023-02-14 | $30.06 | $178K | -8.8% | -20.3% | +8.9% |
| DNLI | SELL | 2023-02-08 | 2023-02-10 | $30.88 | $47K | -8.1% | -19.5% | -4.9% |
| DNLI | SELL · 10b5-1 | 2023-01-09 | 2023-01-10 | $28.48 | $42K | +5.8% | +6.9% | -14.3% |
| DNLI | SELL | 2023-01-05 | 2023-01-09 | $28.49 | $192K | +5.6% | +10.7% | -12.6% |
| DNLI | SELL | 2023-01-04 | 2023-01-05 | $28.69 | $167K | +5.0% | +9.3% | -15.9% |
| DNLI | SELL | 2022-08-23 | 2022-08-25 | $31.98 | $155K | -6.1% | -17.3% | -3.1% |
| DNLI | SELL | 2022-08-19 | 2022-08-23 | $33.22 | $171K | -13.4% | -15.2% | -8.6% |
| DNLI | SELL | 2022-02-11 | 2022-02-15 | $34.71 | $203K | -7.6% | -7.3% | -34.0% |
| DNLI | SELL | 2022-02-09 | 2022-02-11 | $37.10 | $106K | -5.5% | -16.8% | -37.4% |
| DNLI | SELL | 2022-01-05 | 2022-01-07 | $44.78 | $255K | -19.3% | -11.8% | -20.9% |
| DNLI | SELL | 2021-12-06 | 2021-12-08 | $42.52 | $126K | -2.1% | -9.0% | -33.9% |
| DNLI | SELL | 2021-08-23 | 2021-08-25 | $48.91 | $601K | +3.6% | -2.1% | -10.9% |
| DNLI | SELL | 2021-08-19 | 2021-08-23 | $49.58 | $252K | +8.4% | +0.7% | -12.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.